beta

CTIC

CTI BioPharma Corp.

Ctic

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-21-2017 11-08-2016 08-04-2016
Actual EPS -0.23 -0.1 -0.07
Consensus EPS -0.7 -0.07 -0.09
Estimated EPS -0.7 -0.07 -0.09
Number of Estimates 1 1
EPS Surprise $0.47 -$0.03 $0.02

Stats

Summary

CTI BioPharma Corp is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of novel targeted therapies.

Market Cap: 144 Million

Primary Exchange: NASDAQ Capital Market

Website: http://www.ctibiopharma.com

Shares Outstanding: 43 Million

Float: 35.3 Million

Dividend: 0.0 (0.0%)

Beta: 0.734384

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 434 Thousand

Ethical Flags

Animal testing

Longest drawdown: 1395 trading days

From: 2014-01-21 To: 2019-06-12

Lowest Point:

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

via: PR Newswire at 2019-06-13 03:00:00:000

SEATTLE , June 13, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City . Presentation details: About… read more...

CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

via: PR Newswire at 2019-05-29 03:00:00:000

SEATTLE , May 29, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City . Presentation details: The presentati… read more...

CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

via: PR Newswire at 2019-05-29 03:00:00:000

SEATTLE , May 29, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City . Presentation details: The presentati… read more...

CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

via: PR Newswire at 2019-05-29 03:00:00:000

SEATTLE , May 29, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City . Presentation details: The presentati… read more...

CTI BioPharma beats by $0.02

via: SeekingAlpha at 2019-05-02 12:58:00:000

CTI BioPharma (NASDAQ: CTIC ): Q1 GAAP EPS of -$0.19 beats by $0.02 . More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma beats by $0.02

via: SeekingAlpha at 2019-05-02 12:58:00:000

CTI BioPharma (NASDAQ: CTIC ): Q1 GAAP EPS of -$0.19 beats by $0.02 . More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma beats by $0.02

via: SeekingAlpha at 2019-05-02 12:58:00:000

CTI BioPharma (NASDAQ: CTIC ): Q1 GAAP EPS of -$0.19 beats by $0.02 . More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma Reports First Quarter 2019 Financial Results

via: PR Newswire at 2019-05-02 12:05:00:000

SEATTLE , May 2, 2019 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019 . "Advancing our U.S. and European development program for pacritinib for the treatment of myelofibrosis patients with severe t… read more...

CTI BioPharma Reports First Quarter 2019 Financial Results

via: PR Newswire at 2019-05-02 12:05:00:000

SEATTLE , May 2, 2019 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019 . "Advancing our U.S. and European development program for pacritinib for the treatment of myelofibrosis patients with severe t… read more...

CTI BioPharma Reports First Quarter 2019 Financial Results

via: PR Newswire at 2019-05-02 12:05:00:000

SEATTLE , May 2, 2019 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019 . "Advancing our U.S. and European development program for pacritinib for the treatment of myelofibrosis patients with severe t… read more...

CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10

via: PR Newswire at 2019-04-03 03:00:00:000

SEATTLE , April 3, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central. Presentation deta… read more...

CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10

via: PR Newswire at 2019-04-03 03:00:00:000

SEATTLE , April 3, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central. Presentation deta… read more...

CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10

via: PR Newswire at 2019-04-03 03:00:00:000

SEATTLE , April 3, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18 th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central. Presentation deta… read more...

CTI BioPharma reports Q4 results

via: SeekingAlpha at 2019-03-13 12:32:24:000

CTI BioPharma (NASDAQ: CTIC ): Q4 GAAP EPS of $0.01. More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma reports Q4 results

via: SeekingAlpha at 2019-03-13 12:32:24:000

CTI BioPharma (NASDAQ: CTIC ): Q4 GAAP EPS of $0.01. More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma reports Q4 results

via: SeekingAlpha at 2019-03-13 12:32:24:000

CTI BioPharma (NASDAQ: CTIC ): Q4 GAAP EPS of $0.01. More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

via: PR Newswire at 2019-03-13 12:05:00:000

SEATTLE , March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018 . "TheCompany is focused on advancing its development program of pacritinib for the treatment for myelofibros… read more...

CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

via: PR Newswire at 2019-03-13 12:05:00:000

SEATTLE , March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018 . "TheCompany is focused on advancing its development program of pacritinib for the treatment for myelofibros… read more...

CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

via: PR Newswire at 2019-03-13 12:05:00:000

SEATTLE , March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018 . "TheCompany is focused on advancing its development program of pacritinib for the treatment for myelofibros… read more...

CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19

via: PR Newswire at 2019-03-12 03:00:00:000

SEATTLE , March 12, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29 th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central. Presentation d… read more...

CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

via: PR Newswire at 2019-02-20 07:00:00:000

SEATTLE , Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel. The presentat… read more...

CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

via: PR Newswire at 2019-02-20 07:00:00:000

SEATTLE , Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel. The presentat… read more...

CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27

via: PR Newswire at 2019-02-20 07:00:00:000

SEATTLE , Feb. 20, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel. The presentat… read more...

CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

via: PR Newswire at 2019-02-11 07:00:00:000

SEATTLE , Feb. 11, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX (arsenic trioxide). TRISENOX w… read more...

CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

via: PR Newswire at 2019-02-11 07:00:00:000

SEATTLE , Feb. 11, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX (arsenic trioxide). TRISENOX w… read more...

CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

via: PR Newswire at 2019-02-11 07:00:00:000

SEATTLE , Feb. 11, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX (arsenic trioxide). TRISENOX w… read more...

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

via: PR Newswire at 2019-02-01 07:01:00:000

SEATTLE , Feb. 1, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European M… read more...

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

via: PR Newswire at 2019-02-01 07:01:00:000

SEATTLE , Feb. 1, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European M… read more...

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

via: PR Newswire at 2019-02-01 07:01:00:000

SEATTLE , Feb. 1, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European M… read more...

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

via: PR Newswire at 2019-02-01 07:01:00:000

SEATTLE , Feb. 1, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European M… read more...

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

via: PR Newswire at 2019-02-01 07:01:00:000

SEATTLE , Feb. 1, 2019 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis. The decision follows recent interactions with the European M… read more...

CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients?

via: SeekingAlpha at 2019-01-08 15:27:47:000

We covered CTI BioPharma ( CTIC ) in August last year, when we said that if the company can show that its drug pacritinib does better than Jakafi for a certain subset of the myelofibrosis population where Jakafi is not effective, then the company has considerable potential. Recently, we saw … read more...

CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients?

via: SeekingAlpha at 2019-01-08 15:27:47:000

We covered CTI BioPharma ( CTIC ) in August last year, when we said that if the company can show that its drug pacritinib does better than Jakafi for a certain subset of the myelofibrosis population where Jakafi is not effective, then the company has considerable potential. Recently, we saw … read more...

CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients?

via: SeekingAlpha at 2019-01-08 15:27:47:000

We covered CTI BioPharma ( CTIC ) in August last year, when we said that if the company can show that its drug pacritinib does better than Jakafi for a certain subset of the myelofibrosis population where Jakafi is not effective, then the company has considerable potential. Recently, we saw … read more...

Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

via: SeekingAlpha at 2019-01-07 10:13:49:000

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

via: PR Newswire at 2018-12-28 07:00:00:000

SEATTLE , Dec. 28, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 followi… read more...

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

via: PR Newswire at 2018-12-28 07:00:00:000

SEATTLE , Dec. 28, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 followi… read more...

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

via: PR Newswire at 2018-12-28 07:00:00:000

SEATTLE , Dec. 28, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 followi… read more...

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

via: PR Newswire at 2018-12-28 07:00:00:000

SEATTLE , Dec. 28, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 followi… read more...

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

via: PR Newswire at 2018-12-28 07:00:00:000

SEATTLE , Dec. 28, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 followi… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-24 11:55:18:000

Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-24 11:55:18:000

Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-24 11:55:18:000

Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-24 11:55:18:000

Gainers: MINDBODY (NASDAQ: MB ) +67% . Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Renren (NYSE: RENN ) +17% . Destination Maternity (NASDAQ: DEST ) +16% . Savara (NASDAQ: SVRA ) +16% . Dova Pharmaceuticals (NASDAQ: DOVA ) +15% . Aphria (NYSE: APHA ) +14% . Provention Bio (NA… read more...

CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis

via: SeekingAlpha at 2018-12-18 16:17:27:000

Incorporating FDA feedback, CTI BioPharma (NASDAQ: CTIC ) has clarified the principal design of a Phase 3 clinical trial evaluating pacritinib in adult patients with myelofibrosis who have severe thrombocytopenia (low blood platelets). The primary endpoint will be the proportion of patient… read more...

CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis

via: SeekingAlpha at 2018-12-18 16:17:27:000

Incorporating FDA feedback, CTI BioPharma (NASDAQ: CTIC ) has clarified the principal design of a Phase 3 clinical trial evaluating pacritinib in adult patients with myelofibrosis who have severe thrombocytopenia (low blood platelets). The primary endpoint will be the proportion of patient… read more...

CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis

via: SeekingAlpha at 2018-12-18 16:17:27:000

Incorporating FDA feedback, CTI BioPharma (NASDAQ: CTIC ) has clarified the principal design of a Phase 3 clinical trial evaluating pacritinib in adult patients with myelofibrosis who have severe thrombocytopenia (low blood platelets). The primary endpoint will be the proportion of patient… read more...

CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development

via: PR Newswire at 2018-12-18 16:01:00:000

SEATTLE , Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients … read more...

CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development

via: PR Newswire at 2018-12-18 16:01:00:000

SEATTLE , Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients … read more...

CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development

via: PR Newswire at 2018-12-18 16:01:00:000

SEATTLE , Dec. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today that it has received input from the U.S. Food and Drug Administration (FDA) at a recent Type C meeting on key elements of the design of a new randomized Phase 3 study of pacritinib in adult patients … read more...

CTI BioPharma to cut half of workforce in restructuring; shares down 5%

via: SeekingAlpha at 2018-12-13 11:02:31:000

Thinly traded nano cap CTI BioPharma ( CTIC -5.4% ) is down on below-average volume on the heels of its announced restructuring that includes a 50% reduction in headcount. The company says the move should save ~$20M in expenses over the next three years. More news on: CTI BioPharma Cor… read more...

CTI BioPharma to cut half of workforce in restructuring; shares down 5%

via: SeekingAlpha at 2018-12-13 11:02:31:000

Thinly traded nano cap CTI BioPharma ( CTIC -5.4% ) is down on below-average volume on the heels of its announced restructuring that includes a 50% reduction in headcount. The company says the move should save ~$20M in expenses over the next three years. More news on: CTI BioPharma Cor… read more...

CTI BioPharma to cut half of workforce in restructuring; shares down 5%

via: SeekingAlpha at 2018-12-13 11:02:31:000

Thinly traded nano cap CTI BioPharma ( CTIC -5.4% ) is down on below-average volume on the heels of its announced restructuring that includes a 50% reduction in headcount. The company says the move should save ~$20M in expenses over the next three years. More news on: CTI BioPharma Cor… read more...

CTI BioPharma Announces Restructuring Plan

via: PR Newswire at 2018-12-13 10:03:00:000

SEATTLE , Dec. 13, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of th… read more...

CTI BioPharma Announces Restructuring Plan

via: PR Newswire at 2018-12-13 10:03:00:000

SEATTLE , Dec. 13, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of th… read more...

CTI BioPharma Announces Restructuring Plan

via: PR Newswire at 2018-12-13 10:03:00:000

SEATTLE , Dec. 13, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) announced today a restructuring plan to improve efficiencies and reduce costs within the organization. As part of this plan, workforce reductions have been implemented that impact approximately 50 percent of th… read more...

CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency

via: PR Newswire at 2018-11-26 16:01:00:000

SEATTLE , Nov. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company has received a second round of questions related to the Day 180 List of Outstanding Issues, for the marketing authorization application (MAA) for pacritinib, from the European Medici… read more...

CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency

via: PR Newswire at 2018-11-26 16:01:00:000

SEATTLE , Nov. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company has received a second round of questions related to the Day 180 List of Outstanding Issues, for the marketing authorization application (MAA) for pacritinib, from the European Medici… read more...

CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency

via: PR Newswire at 2018-11-26 16:01:00:000

SEATTLE , Nov. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company has received a second round of questions related to the Day 180 List of Outstanding Issues, for the marketing authorization application (MAA) for pacritinib, from the European Medici… read more...

European advisory group backs CTI Bio's pacritinib for certain myelofibrosis patients

via: SeekingAlpha at 2018-11-16 08:48:16:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for CTI BioPharma's (NASDAQ: CTIC ) pacritinib for the treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia… read more...

European advisory group backs CTI Bio's pacritinib for certain myelofibrosis patients

via: SeekingAlpha at 2018-11-16 08:48:16:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for CTI BioPharma's (NASDAQ: CTIC ) pacritinib for the treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia… read more...

European advisory group backs CTI Bio's pacritinib for certain myelofibrosis patients

via: SeekingAlpha at 2018-11-16 08:48:16:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for CTI BioPharma's (NASDAQ: CTIC ) pacritinib for the treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia… read more...

European advisory group backs CTI Bio's pacritinib for certain myelofibrosis patients

via: SeekingAlpha at 2018-11-16 08:48:16:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for CTI BioPharma's (NASDAQ: CTIC ) pacritinib for the treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia… read more...

European advisory group backs CTI Bio's pacritinib for certain myelofibrosis patients

via: SeekingAlpha at 2018-11-16 08:48:16:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval for CTI BioPharma's (NASDAQ: CTIC ) pacritinib for the treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:33:12:000

CTI BioPharma Corp. (CTIC) Q3 2018 Results Earnings Conference Call November 1, 2018, 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Analysts Konstantinos Ap… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:33:12:000

CTI BioPharma Corp. (CTIC) Q3 2018 Results Earnings Conference Call November 1, 2018, 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Analysts Konstantinos Ap… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:33:12:000

CTI BioPharma Corp. (CTIC) Q3 2018 Results Earnings Conference Call November 1, 2018, 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Analysts Konstantinos Ap… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:33:12:000

CTI BioPharma Corp. (CTIC) Q3 2018 Results Earnings Conference Call November 1, 2018, 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Analysts Konstantinos Ap… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:33:12:000

CTI BioPharma Corp. (CTIC) Q3 2018 Results Earnings Conference Call November 1, 2018, 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Analysts Konstantinos Ap… read more...

CTI BioPharma misses on revenue

via: SeekingAlpha at 2018-11-01 08:08:20:000

CTI BioPharma (NASDAQ: CTIC ): Q3 GAAP EPS of -$0.26. Revenue of $0.72M (-57.6% Y/Y) misses by $0.01M . Press Release More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , read more...

CTI BioPharma Reports Third Quarter 2018 Financial Results

via: PR Newswire at 2018-11-01 08:01:00:000

SEATTLE , Nov. 1, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the third quarter and nine months ended September 30, 2018 . In October 2018 , CTI BioPharma announced the continuation of the PAC203 Phase 2 study without modification, … read more...

CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018

via: PR Newswire at 2018-10-25 07:01:00:000

SEATTLE , Oct. 25, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results onThursday, November 1, 2018, after the close of the U.S. financial markets. Following th… read more...

CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018

via: PR Newswire at 2018-10-25 07:01:00:000

SEATTLE , Oct. 25, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results onThursday, November 1, 2018, after the close of the U.S. financial markets. Following th… read more...

CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018

via: PR Newswire at 2018-10-25 07:01:00:000

SEATTLE , Oct. 25, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results onThursday, November 1, 2018, after the close of the U.S. financial markets. Following th… read more...

CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

via: PR Newswire at 2018-10-01 07:01:00:000

SEATTLE , Oct. 1, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The ID… read more...

CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

via: PR Newswire at 2018-10-01 07:01:00:000

SEATTLE , Oct. 1, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The ID… read more...

CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

via: PR Newswire at 2018-10-01 07:01:00:000

SEATTLE , Oct. 1, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The ID… read more...

CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

via: PR Newswire at 2018-09-26 07:01:00:000

SEATTLE , Sept. 26, 2018 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel. Presentation d… read more...

CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

via: PR Newswire at 2018-09-26 07:01:00:000

SEATTLE , Sept. 26, 2018 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel. Presentation d… read more...

CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

via: PR Newswire at 2018-09-26 07:01:00:000

SEATTLE , Sept. 26, 2018 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel. Presentation d… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-02 21:39:11:000

CTI BioPharma Corp. (CTIC) Q2 2018 Earnings Conference Call August 02, 2018 04:30 PM ET Executives Julia Balanova - Solebury Trout Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer… read more...

CTI BioPharma beats by $0.03, misses on revenue

via: SeekingAlpha at 2018-08-02 16:34:52:000

CTI BioPharma (NASDAQ: CTIC ): Q2 EPS of -$0.20 beats by $0.03 . More news on: CTI BioPharma Corp., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

CTI BioPharma Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-08-02 08:00:00:000

SEATTLE , Aug. 2, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter and six months ended June 30, 2018 . In July 2018 , CTI BioPharma announced the continuation without modification of the PAC203 Phase 2 study following… read more...

CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018

via: PR Newswire at 2018-07-26 16:01:00:000

SEATTLE , July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results onThursday, August 2, 2018, after the close of the U.S. financial markets. Following the announce… read more...

CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018

via: PR Newswire at 2018-07-26 16:01:00:000

SEATTLE , July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results onThursday, August 2, 2018, after the close of the U.S. financial markets. Following the announce… read more...

CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018

via: PR Newswire at 2018-07-26 16:01:00:000

SEATTLE , July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results onThursday, August 2, 2018, after the close of the U.S. financial markets. Following the announce… read more...

3 Things In Biotech, July 21: Does CTI Really Deserve To Tank?

via: SeekingAlpha at 2018-07-21 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche hasn't quite hit the mark in lung cancer… yet Company: Roche ( RHHBY ) ( RHHBF ) Therapy: Atezolizumab ... read more...

3 Things In Biotech, July 21: Does CTI Really Deserve To Tank?

via: SeekingAlpha at 2018-07-21 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche hasn't quite hit the mark in lung cancer… yet Company: Roche ( RHHBY ) ( RHHBF ) Therapy: Atezolizumab ... read more...

3 Things In Biotech, July 21: Does CTI Really Deserve To Tank?

via: SeekingAlpha at 2018-07-21 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche hasn't quite hit the mark in lung cancer… yet Company: Roche ( RHHBY ) ( RHHBF ) Therapy: Atezolizumab ... read more...

3 Things In Biotech, July 21: Does CTI Really Deserve To Tank?

via: SeekingAlpha at 2018-07-21 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche hasn't quite hit the mark in lung cancer… yet Company: Roche ( RHHBY ) ( RHHBF ) Therapy: Atezolizumab ... read more...

Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

via: SeekingAlpha at 2018-07-20 09:00:53:000

Stocks in News: CBIO, CTIC Catalyst Bio's marzeptacog alfa shows positive action in hemophilia study Discussion : Catalyst Biosciences ( CBIO ) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptac… read more...

Midday Gainers / Losers (07/18/2018)

via: SeekingAlpha at 2018-07-18 12:51:44:000

Gainers: CPAH +55% . STAF +39% . MTSL +31% . CHRS +19% . EBF +15% . NXTD +13% . NMRD +13% . BBOX +12% . GWW +12% . ARC +11% . More news on: CounterPath Corporation, Staffing 360 Solutions, Inc., MER Telemanagement Solutions Ltd., Stocks on the move, , … read more...

Midday Gainers / Losers (07/18/2018)

via: SeekingAlpha at 2018-07-18 12:51:44:000

Gainers: CPAH +55% . STAF +39% . MTSL +31% . CHRS +19% . EBF +15% . NXTD +13% . NMRD +13% . BBOX +12% . GWW +12% . ARC +11% . More news on: CounterPath Corporation, Staffing 360 Solutions, Inc., MER Telemanagement Solutions Ltd., Stocks on the move, , … read more...

Premarket Losers as of 9:05 am (7/18/2018)

via: SeekingAlpha at 2018-07-18 09:13:11:000

CTIC -25% after initiating late-stage study of pacritinib in myelofibrosis in 2019. More news on: CTI BioPharma Corp., Ameri Holdings, Inc., Catalyst Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (7/18/2018)

via: SeekingAlpha at 2018-07-18 09:13:11:000

CTIC -25% after initiating late-stage study of pacritinib in myelofibrosis in 2019. More news on: CTI BioPharma Corp., Ameri Holdings, Inc., Catalyst Inc., Stocks on the move, , Read more … read more...

CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

via: PR Newswire at 2018-07-18 07:00:00:000

SEATTLE , July 18, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory p… read more...

CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

via: PR Newswire at 2018-07-18 07:00:00:000

SEATTLE , July 18, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory p… read more...

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

via: SeekingAlpha at 2018-07-11 12:12:40:000

Stocks in News: IsoRay +143% after FDA clears brachytherapy technology Note : ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is whe… read more...

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

via: SeekingAlpha at 2018-07-11 12:12:40:000

Stocks in News: IsoRay +143% after FDA clears brachytherapy technology Note : ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is whe… read more...

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

via: SeekingAlpha at 2018-07-11 12:12:40:000

Stocks in News: IsoRay +143% after FDA clears brachytherapy technology Note : ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is whe… read more...

3 Things In Biotech, June 10: Can CTI Salvage Bad News?

via: SeekingAlpha at 2018-07-10 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CTI Biopharma falters in non-Hodgkin lymphoma Company: CTI Biopharma ( CTIC ) Therapy: Pi… read more...

Midday Gainers / Losers (07/09/2018)

via: SeekingAlpha at 2018-07-09 12:42:43:000

Gainers: STAF +255% . BNTC +56% . EVK +26% . OTCPK:LFIN +17% . LEDS +15% . HELE +16% . NNDM +15% . TAT +14% . BBOX +12% . PVG +12% . More news on: Staffing 360 Solutions, Inc., Benitec, Ever-Glory International Group, Inc, Stocks on the move, , Rea… read more...

Premarket Losers as of 9:05 am (07/09/2018)

via: SeekingAlpha at 2018-07-09 09:22:02:000

CTIC -19% as it flunks late-stage NHL study . More news on: CTI BioPharma Corp., Stocks on the move, Read more … read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

CTI Bio's Pixuvri flunks late-stage NHL study; shares halted

via: SeekingAlpha at 2018-07-09 07:20:43:000

Thinly traded micro cap CTI BioPharma (NASDAQ: CTIC ) is set for a significant down move after announcing that a Phase 3 clinical trial, PIX306 , evaluating PIXUVRI (pixantrone), combined with Roche's Rituxan (rituximab), in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) faile… read more...

Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma

via: PR Newswire at 2018-07-09 07:00:00:000

SEATTLE , July 9,2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) and Servier today announced that the pivotal Phase III trial (PIX306) evaluating PIXUVRI (pixantrone) combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressiv… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

CTI Bio's mid-stage study of pacritinib in myelofibrosis to continue as planned; shares up 3%

via: SeekingAlpha at 2018-07-02 11:13:39:000

Thinly traded micro cap CTI BioPharma ( CTIC +2.6% ) is up on below-average volume on the heels of its announcement that its Phase 2 clinical trial, PAC203 , assessing JAK2 inhibitor pacritinib in myelofibrosis patients previously treated with Incyte's Jakafi (ruxolitinib) will continue… read more...

CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib

via: PR Newswire at 2018-07-02 07:00:00:000

SEATTLE , July 2, 2018 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee (IDMC) of PAC203, the study will continue without modification and that a second interim review will be c… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference

via: PR Newswire at 2018-06-14 07:02:00:000

SEATTLE , June 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York, NY on Thursday, June 21, 2018 at 1:00 PM ET . The presentation will be webcast li… read more...

CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference

via: PR Newswire at 2018-06-14 07:02:00:000

SEATTLE , June 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York, NY on Thursday, June 21, 2018 at 1:00 PM ET . The presentation will be webcast li… read more...

CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference

via: PR Newswire at 2018-06-06 07:01:00:000

SEATTLE , June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings. The presen… read more...

CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference

via: PR Newswire at 2018-06-06 07:01:00:000

SEATTLE , June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings. The presen… read more...

CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference

via: PR Newswire at 2018-06-06 07:01:00:000

SEATTLE , June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings. The presen… read more...

CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference

via: PR Newswire at 2018-06-06 07:01:00:000

SEATTLE , June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings. The presen… read more...

CTI BioPharma's (CTIC) CEO Adam Craig on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-03 22:48:04:000

CTI BioPharma Corp. (CTIC) Q1 2018 Earnings Conference Call May 3, 2018 16:30 ET Executives Tricia Truehart - Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer Analysts Gill … read more...

CTI BioPharma's (CTIC) CEO Adam Craig on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-03 22:48:04:000

CTI BioPharma Corp. (CTIC) Q1 2018 Earnings Conference Call May 3, 2018 16:30 ET Executives Tricia Truehart - Investor Relations Adam Craig - President and Chief Executive Officer David Kirske - Chief Financial Officer Bruce Seeley - Chief Operating Officer Analysts Gill … read more...

CTI BioPharma beats by $0.02, beats on revenue

via: SeekingAlpha at 2018-05-03 16:08:16:000

CTI BioPharma (NASDAQ: CTIC ): Q1 EPS of -$0.08 beats by $0.02 . More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma beats by $0.02, beats on revenue

via: SeekingAlpha at 2018-05-03 16:08:16:000

CTI BioPharma (NASDAQ: CTIC ): Q1 EPS of -$0.08 beats by $0.02 . More news on: CTI BioPharma Corp., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

CTI BioPharma Reports First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-03 16:01:00:000

SEATTLE , May 3, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the first quarter ended March 31, 2018 . In March 2018 , results from the Phase 3 PERSIST-2 clinical trial of pacritinib were published online in JAMA Oncology . The randomize… read more...

CTI BioPharma Reports First Quarter 2018 Financial Results

via: PR Newswire at 2018-05-03 16:01:00:000

SEATTLE , May 3, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the first quarter ended March 31, 2018 . In March 2018 , results from the Phase 3 PERSIST-2 clinical trial of pacritinib were published online in JAMA Oncology . The randomize… read more...

CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018

via: PR Newswire at 2018-04-26 16:05:00:000

SEATTLE , April 26, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2018 financial results onThursday, May 3, 2018, after the close of the U.S. financial markets. Following the announ… read more...

CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018

via: PR Newswire at 2018-04-26 16:05:00:000

SEATTLE , April 26, 2018 /PRNewswire/ --CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2018 financial results onThursday, May 3, 2018, after the close of the U.S. financial markets. Following the announ… read more...

We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers

via: SeekingAlpha at 2018-04-26 08:30:00:000

Janssen has removed or omitted imetelstat from key presentation materials We believe Geron (GERN) bulls are missing a key piece of evidence that suggests to us that Janssen (JNJ) is likely to terminate its licensing agreement for imetelstat. In every Johnson & Johnson (Janssen&#x2019… read more...

We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers

via: SeekingAlpha at 2018-04-26 08:30:00:000

Janssen has removed or omitted imetelstat from key presentation materials We believe Geron (GERN) bulls are missing a key piece of evidence that suggests to us that Janssen (JNJ) is likely to terminate its licensing agreement for imetelstat. In every Johnson & Johnson (Janssen&#x2019… read more...

Seeing Value In CTI BioPharma: Compelling Data, Recent M&A Validate Pacritinib In Myelofibrosis

via: SeekingAlpha at 2018-03-27 11:52:25:000

We have published an investment thesis on four biotech companies thus far; three of which have generated exceptional returns ( SBBP, INSM, EDGE) . We were recently interviewed by Seeking Alpha where we shared a brief long thesis for CTI BioPharma ( CTIC ). This article constitutes an in-… read more...

Seeing Value In CTI BioPharma: Compelling Data, Recent M&A Validate Pacritinib In Myelofibrosis

via: SeekingAlpha at 2018-03-27 11:52:25:000

We have published an investment thesis on four biotech companies thus far; three of which have generated exceptional returns ( SBBP, INSM, EDGE) . We were recently interviewed by Seeking Alpha where we shared a brief long thesis for CTI BioPharma ( CTIC ). This article constitutes an in-… read more...

SA Interview: Biotechnology Investing With Juggernaut Capital

via: SeekingAlpha at 2018-03-18 07:30:00:000

Feature interview Juggernaut Capital is a private long/short equity fund focused on supporting innovation in life sciences. Notable calls include a bullish thesis on Strongbridge Biopharma (SBBP), bullish thesis on Insmed (INSM), and bullish thesis on Edge Therapeutics (EDGE). We e… read more...

SA Interview: Biotechnology Investing With Juggernaut Capital

via: SeekingAlpha at 2018-03-18 07:30:00:000

Feature interview Juggernaut Capital is a private long/short equity fund focused on supporting innovation in life sciences. Notable calls include a bullish thesis on Strongbridge Biopharma (SBBP), bullish thesis on Insmed (INSM), and bullish thesis on Edge Therapeutics (EDGE). We e… read more...

Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC

via: SeekingAlpha at 2018-03-10 08:00:00:000

Analysis of top Seeking Alpha coverage: Immuron Today, we will discuss Immuron ( IMRN ) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in … read more...

Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC

via: SeekingAlpha at 2018-03-10 08:00:00:000

Analysis of top Seeking Alpha coverage: Immuron Today, we will discuss Immuron ( IMRN ) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in … read more...

Late-stage data on CTI's pacritinib published in JAMA Oncology

via: SeekingAlpha at 2018-03-09 07:27:09:000

CTI BioPharma (NASDAQ: CTIC ) announces that results from the Phase 3 PERSIST-2 study evaluating JAK2 inhibitor pacritinib in patients with myelofibrosis and thrombocytopenia have been published online in JAMA Oncology . More news on: CTI BioPharma Corp., Healthcare stocks news, R… read more...

Late-stage data on CTI's pacritinib published in JAMA Oncology

via: SeekingAlpha at 2018-03-09 07:27:09:000

CTI BioPharma (NASDAQ: CTIC ) announces that results from the Phase 3 PERSIST-2 study evaluating JAK2 inhibitor pacritinib in patients with myelofibrosis and thrombocytopenia have been published online in JAMA Oncology . More news on: CTI BioPharma Corp., Healthcare stocks news, R… read more...

CTI BioPharma to Present at Upcoming Investor Conferences

via: PR Newswire at 2018-03-09 07:05:00:000

SEATTLE , March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences during the month of March: 30 th Annual Roth Conference in Laguna Niguel, CA Dat… read more...

CTI BioPharma to Present at Upcoming Investor Conferences

via: PR Newswire at 2018-03-09 07:05:00:000

SEATTLE , March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences during the month of March: 30 th Annual Roth Conference in Laguna Niguel, CA Dat… read more...

CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock

via: PR Newswire at 2018-02-13 07:00:00:000

SEATTLE , Feb. 13, 2018 /PRNewswire/ --CTI BioPharma Corp. ("CTI BioPharma") (NASDAQ: CTIC) today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock…. read more...

Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data

via: SeekingAlpha at 2018-02-10 08:00:00:000

Analysis of top Seeking Alpha coverage: GW Pharmaceuticals Today we will discuss GW Pharmaceuticals ( GWPH ), which after a solid run over the past six months has seen a sharp pullback in its shares during the recent sell-off in the broader market. GW Pharmaceuticals posted robust ga… read more...

Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data

via: SeekingAlpha at 2018-02-10 08:00:00:000

Analysis of top Seeking Alpha coverage: GW Pharmaceuticals Today we will discuss GW Pharmaceuticals ( GWPH ), which after a solid run over the past six months has seen a sharp pullback in its shares during the recent sell-off in the broader market. GW Pharmaceuticals posted robust ga… read more...

Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data

via: SeekingAlpha at 2018-02-10 08:00:00:000

Analysis of top Seeking Alpha coverage: GW Pharmaceuticals Today we will discuss GW Pharmaceuticals ( GWPH ), which after a solid run over the past six months has seen a sharp pullback in its shares during the recent sell-off in the broader market. GW Pharmaceuticals posted robust ga… read more...

Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data

via: SeekingAlpha at 2018-02-10 08:00:00:000

Analysis of top Seeking Alpha coverage: GW Pharmaceuticals Today we will discuss GW Pharmaceuticals ( GWPH ), which after a solid run over the past six months has seen a sharp pullback in its shares during the recent sell-off in the broader market. GW Pharmaceuticals posted robust ga… read more...

Premarket Gainers as of 9:05 am (02/09/2018)

via: SeekingAlpha at 2018-02-09 09:21:15:000

AOI +48% on Q3 result . More news on: Alliance One International, Inc., Inpixon, Castle Brands Inc, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (02/09/2018)

via: SeekingAlpha at 2018-02-09 09:21:15:000

AOI +48% on Q3 result . More news on: Alliance One International, Inc., Inpixon, Castle Brands Inc, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (02/09/2018)

via: SeekingAlpha at 2018-02-09 09:21:15:000

AOI +48% on Q3 result . More news on: Alliance One International, Inc., Inpixon, Castle Brands Inc, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (02/09/2018)

via: SeekingAlpha at 2018-02-09 09:21:15:000

AOI +48% on Q3 result . More news on: Alliance One International, Inc., Inpixon, Castle Brands Inc, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (02/09/2018)

via: SeekingAlpha at 2018-02-09 09:21:15:000

AOI +48% on Q3 result . More news on: Alliance One International, Inc., Inpixon, Castle Brands Inc, Stocks on the move, , Read more … read more...

CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock

via: PR Newswire at 2018-02-09 07:00:00:000

SEATTLE , Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPhar… read more...

CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock

via: PR Newswire at 2018-02-09 07:00:00:000

SEATTLE , Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPhar… read more...

CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock

via: PR Newswire at 2018-02-09 07:00:00:000

SEATTLE , Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPhar… read more...

CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock

via: PR Newswire at 2018-02-09 07:00:00:000

SEATTLE , Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPhar… read more...

CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock

via: PR Newswire at 2018-02-09 07:00:00:000

SEATTLE , Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp.(CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPhar… read more...

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

via: SeekingAlpha at 2018-02-06 08:00:00:000

Analysis of top Seeking Alpha coverage: AMAG Pharmaceuticals Today we will discuss AMAG Pharmaceuticals ( AMAG ), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia ( IDA ) who are … read more...

CTI Biopharma launches follow-on offering of common stock

via: SeekingAlpha at 2018-02-05 08:18:03:000

CTI BioPharma(NASDAQ: CTIC ) launches a public offering of shares of its common stock. More news on: CTI BioPharma Corp., Healthcare stocks news, Stocks on the move, Read more … read more...

CTI BioPharma Announces Launch of Follow-On Offering

via: PR Newswire at 2018-02-05 07:55:00:000

SEATTLE , Feb. 5, 2018 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the launch of a proposed underwritten public offering of shares of its common stock. In addition, CTI BioPharma expects to grant the underwriters a 30-day option to purchase addi… read more...

3 Things In Biotech You Should Learn Today: January 28, 2018

via: SeekingAlpha at 2018-01-29 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 28, 2018

via: SeekingAlpha at 2018-01-29 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

3 Things In Biotech You Should Learn Today: January 28, 2018

via: SeekingAlpha at 2018-01-29 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...

CTI BioPharma Provides Corporate and European Regulatory Update

via: PR Newswire at 2018-01-25 16:40:00:000

SEATTLE , Jan. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that it has been reincorporated in the State of Delaware following a Special Meeting of Shareholders, triggering an automatic delisting of CTI's common stock from the Borsa Italian… read more...

CTI BioPharma Provides Corporate and European Regulatory Update

via: PR Newswire at 2018-01-25 16:40:00:000

SEATTLE , Jan. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that it has been reincorporated in the State of Delaware following a Special Meeting of Shareholders, triggering an automatic delisting of CTI's common stock from the Borsa Italian… read more...

Stocks To Watch: Earnings Season Hits Higher Gear

via: SeekingAlpha at 2018-01-20 08:27:52:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. By all appearances it's going to take a lot to knock the stock market off its 2018 … read more...

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

via: SeekingAlpha at 2018-01-19 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...

CTI BioPharma earns $10M milestone from Teva on U.S. OK of Trisenox

via: SeekingAlpha at 2018-01-18 07:13:57:000

The FDA's approval of Teva Pharmaceutical Industries' (NYSE: TEVA ) TRISENOX (arsenic trioxide) for first-line acute promyelocytic leukemia triggered a $10M milestone to CTI BioPharma (NASDAQ: CTIC ). More news on: Teva Pharmaceutical Industries Limited, CTI BioPharma Corp., Healthcare s… read more...

CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®

via: PR Newswire at 2018-01-18 01:30:00:000

SEATTLE , Jan. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it expects to receive a$10 millionmilestone payment in February, 2018 fromTeva Pharmaceutical Industries Ltd. related to the achievement of a milestone for U.S. F… read more...

CTI BioPharma Loses Strength As The Company Faces Sharp Revenue Decline

via: SeekingAlpha at 2017-12-20 17:56:34:000

CTI BioPharma Corp. (NASDAQ: CTIC ) stock showed a steady decline this year, on the back of several setbacks suffered by the company. The company reported steady decline in its revenue in the third quarter while its NDA for its potential blockbuster drug Pacritinib had to be withdrawn. While… read more...

Premarket Losers as of 9:05 am

via: SeekingAlpha at 2017-11-28 09:13:00:000

MARA -24% . More news on: Marathon Patent Group, Inc., Digital Power Corporation, Xunlei Limited, Stocks on the move, Read more … read more...

Planned equity offering roundup - healthcare

via: SeekingAlpha at 2017-11-08 09:41:42:000

Recent SEC filings (S-3) for planned equity offerings: More news on: Chimerix Inc, PAVmed Inc., Cumberland Pharmaceuticals Inc., Healthcare stocks news, Read more … read more...

CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference

via: PR Newswire at 2017-11-08 01:30:00:000

SEATTLE , Nov. 8, 2017 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the Jefferies 2017 London Healthcare Conference Wednesday, November 15, 2017 at 12:20 p.m. ET / 5:20 p.m. GMT in London . The … read more...

CTI BioPharma's (CTIC) CEO Adam Craig on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-06 18:56:04:000

CTI BioPharma Corp. (CTIC) Q3 2017 Results Earnings Conference Call November 06, 2017 04:30 PM ET Executives Ed Bell - IR Adam Craig - President and CEO David Kirske - CFO Bruce Seeley - COO Jack Singer - Chief Scientific Officer Analysts Matthew Andrews - Jefferies B… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2017-01-03 10.0 1.0 10.0
Data provided for free by IEX